Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER - survey).

Ashish Sharma,Frank G Holz,Carl D Regillo,K Bailey Freund,David Sarraf,Arshad M Khanani,Caroline Baumal,Nancy Holekamp,Ramin Tadayoni,Nilesh Kumar,Nikulaa Parachuri,Baruch D Kuppermann,Francesco Bandello,Giuseppe Querques,Anat Loewenstein,Şengül Özdek, Kourous Rezai, Kodjikian Laurent,Alper Bilgic,Paolo Lanzetta,Dinah Zur,Nicolas Yannuzzi,Giulia Corradetti,Peter Kaiser,Assaf Hilely, David Boyer, Aleksandra Rachitskaya,Usha Chakravarthy,Maximilian Wintergerst, Valentina Sarao,Barbara Parolini,Prithvi Mruthyunjaya, Quan Dong Nguyen, Diana DO,Pearse A Keane, Tarek Hassan, Jayanth Sridhar,David Eichenbaum,Dilraj Grewal, Martin Splitzer

Expert opinion on biological therapy（2023）

引用 3|浏览22

暂无评分

摘要

The Bio-USER survey revealed that while the majority of retinal physicians need additional information regarding the safety, efficacy and immunogenicity when making clinical decisions regarding their use. Retinal physicians from US are more comfortable in continuing to use off-label bevacizumab compared to physicians from Europe.

查看译文

关键词

Anti-VEGF,Bio-USER,United States,awareness,biosimilar,europe,ophthalmology,retina,survey

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要